<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>MedWorm Tags: chronic obstructive pulmonary disease</title>
        <description>MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'chronic obstructive pulmonary disease'.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=%22chronic+obstructive+pulmonary+disease%22&t=%22chronic+obstructive+pulmonary+disease%22&r=Exact&o=d&f=tag]]></link>
        <lastBuildDate>Sat, 03 Sep 2011 02:17:46 +0100</lastBuildDate>
        <item>
            <title>Managing COPD as a Long Term Condition: Emerging Learning from the National Improvement Projects</title>
            <link>http://www.medworm.com/index.php?rid=5158852&amp;cid=t_105518_86_f&amp;fid=36669&amp;url=http%3A%2F%2Ffadelibrary.wordpress.com%2F2011%2F08%2F23%2Fmanaging-copd-as-a-long-term-condition-emerging-learning-from-the-national-improvement-projects%2F</link>
            <description>Scan or click to download &amp;#039;Managing COPD as a Long Term Condition: Emerging Learning from the National Improvement Projects&amp;#039;
Title: Managing COPD as a Long Term Condition: Emerging Learning from the National Improvement Projects
The Skinny: Report from NHS Improvement offering top tips for COPD management projects and service improvement.
Just giving patients a plan and telling them what they should do probably won’t change behaviour:
Effort, time and skills are needed to build rapport and focus on the person’s own goals and motivation so that they want to do the right thing
Different approaches work for different people
The more time you invest up front with people, the less frequently you will probably see them – this and how to optimise resources are being tested
To Impr...</description>
            <author>Fade Library</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5158852</comments>
            <pubDate>Tue, 23 Aug 2011 16:09:42 +0100</pubDate>
            <guid isPermaLink="false">5158852</guid>        </item>
        <item>
            <title>Breathe Deeply: Spiriva Studies Show Troubling Pattern Of Serious Heart Risks, If You Know Where To Look</title>
            <link>http://www.medworm.com/index.php?rid=5029211&amp;cid=t_105518_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F2TajULYXlqU%2F</link>
            <description>Last month, a widely publicized study raised concerns about the safety of the blockbuster Spiriva inhaler that is used to treat chronic obstructive pulmonary disease. The meta-analysis published in the British Medical Journal found that, when administered in the mist form known as Respimat, there was a 52 percent increase in mortality risk compared with a placebo (see here).
Not surprisingly, Boehringer Ingelheim, which makes the inhaler, disagreed. And in disputing the findings, the drugmaker made a point of saying the results were not based on new clinical evidence and that the meta-analysis relied on already publicly available data. BI also maintained that “robust evidence” has also been published about the safety of the older, powder version known as HandiHaler (read the statement)...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5029211</comments>
            <pubDate>Thu, 14 Jul 2011 16:25:23 +0100</pubDate>
            <guid isPermaLink="false">5029211</guid>        </item>
        <item>
            <title>EU Closes Antitrust Probe Into Boehringer</title>
            <link>http://www.medworm.com/index.php?rid=5008666&amp;cid=t_105518_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fb0Td2mZIFjs%2F</link>
            <description>European Union antitrust regulators have ended a four-year probe into charges that Boehringer Ingelheim abused the patent system to thwart rivals from launching versions of the best-selling Spiriva med for treating chronic obstructive pulmonary disease, or COPD. To settle the investigation, the German drugmaker agreed to make changes in its intellectual property protections.
As the EU noted, Boehringer is the market leader in COPD meds thanks to its Spiriva inhalers, which generated nearly $4.3 billion in sales last year. The fracas began, though, in 2003, when Boehringer filed patent applications for new treatments involving combinations of three categories of active substances, including a new active substance that was discovered by Almirall, a Spanish drugmaker.
Almirall objected to the...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5008666</comments>
            <pubDate>Thu, 07 Jul 2011 12:15:21 +0100</pubDate>
            <guid isPermaLink="false">5008666</guid>        </item>
        <item>
            <title>Vitamin D For COPD: Why That Won’t Be Enough</title>
            <link>http://www.medworm.com/index.php?rid=4934160&amp;cid=t_105518_87_f&amp;fid=39187&amp;url=http%3A%2F%2Fgetbetterhealth.com%2Fvitamin-d-for-copd-why-that-wont-be-enough%2F2011.06.16</link>
            <description>I am frequently extolling the health benefits of Vitamin D because almost weekly there is a new study that correlates high vitamin D levels with reducing some disease.  The latest is from the American Journal of Respiratory and Critical Care Medicine and research shows that high doses of vitamin D supplementation improved respiratory muscle strength in patients with Chronic Obstructive Pulmonary Disease (COPD).  The patients that did not receive supplemental vitamin D had blood levels of 22.8 compared to 53.8 in the supplemented group.  The patients who were supplemented had improved respiratory function, strength and less shortness of breath.  It certainly didn&amp;#8217;t cure or reverse COPD but the improvement was an encouraging trend in this terrible chronic disease.
In reading about ...</description>
            <author>Better Health</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4934160</comments>
            <pubDate>Thu, 16 Jun 2011 14:00:00 +0100</pubDate>
            <guid isPermaLink="false">4934160</guid>        </item>
        <item>
            <title>One More Window</title>
            <link>http://www.medworm.com/index.php?rid=4758749&amp;cid=t_105518_87_f&amp;fid=38368&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FDisruptiveWomenInHealthCare%2F%7E3%2FkqNmcpWq5kw%2F</link>
            <description>This guest post was written by Nalini Saligram, PhD, founder and CEO of Arogya World. It originally ran on Arogya World&amp;#8217;s blog on April 22nd.
On Earth Day, which was marked recently on April 22, 2011, we generally tend to focus on the impact of people on the planet. But it is equally important to consider the impact of pollution on people and health including non-communicable diseases  (NCDs). 
NCDs, which include cardiovascular disease, diabetes, cancers and chronic lung disease, are gaining much-needed attention this year in advance of the upcoming pivotal UN High-level Meeting on NCDs on September 19-20.  NCDs &amp;#8211; yes, the word is hard to pronounce and doesn’t quite roll off our tongues easily, but I am sure HIV/AIDS was quite a mouthful too in the early years &amp;#8211; cau...</description>
            <author>Disruptive Women in Health Care</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4758749</comments>
            <pubDate>Wed, 27 Apr 2011 13:43:40 +0100</pubDate>
            <guid isPermaLink="false">4758749</guid>        </item>
        <item>
            <title>Nursing Times 2011 (V. 107 No. 15/16)</title>
            <link>http://www.medworm.com/index.php?rid=4758710&amp;cid=t_105518_86_f&amp;fid=36669&amp;url=http%3A%2F%2Ffadelibrary.wordpress.com%2F2011%2F04%2F27%2Fnursing-times-2011-v-107-no-1516%2F</link>
            <description>This article examines the technology of telehealth as a tool to manage COPD. Literature suggests that telehealth can reduce hospital admissions and bed days, and boost patient satisfaction but more research is needed to establish whether these technologies are safe, efficient and economical.
Contact the Library for a copy of this article.
Filed under: Current Awareness, Journals Tagged: Chronic Obstructive Pulmonary Disease, COPD, Telecare, Telehealth, Telemedicine, Telemonitoring (Source: Fade Library)</description>
            <author>Fade Library</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4758710</comments>
            <pubDate>Wed, 27 Apr 2011 09:42:43 +0100</pubDate>
            <guid isPermaLink="false">4758710</guid>        </item>
        <item>
            <title>HHS Told To Probe ‘Unethical’ Novartis Trials</title>
            <link>http://www.medworm.com/index.php?rid=4600793&amp;cid=t_105518_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FE8s7is_0mk0%2F</link>
            <description>The federal government was asked by a watchdog group to investigate several allegedly &amp;#8220;unethical long-term, placebo-controlled studies&amp;#8221; for indacterol, a Novartis drug for treating moderate to severe chronic obstructuve pulmonary disease. Why? &amp;#8220;The studies were marred by a failure to minimize risk to subjects and inadequate information provided to subjects,&amp;#8221; according to Public Citizen.
In a letter sent to the Office for Human Research Protections at the US Department of Health and Human Services, the group alleges there six &amp;#8220;unethical&amp;#8221; studies in which placebo-control subjects received prolonged substandard care. Put another way, Public Citizen charges the patients were prevented from using widely acknowledged standard care and that informed consent was...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4600793</comments>
            <pubDate>Wed, 16 Mar 2011 17:47:48 +0100</pubDate>
            <guid isPermaLink="false">4600793</guid>        </item>
        <item>
            <title>Pharmalot… Pharmalittle… Good Morning</title>
            <link>http://www.medworm.com/index.php?rid=3965697&amp;cid=t_105518_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FCSt3qKYXFWs%2F</link>
            <description>Top of the morning to you. We are scurrying about in hopes of depositing one of the short people at the local schoolhouse. As always, this requires fortitude and a cup of stimulation. Meanwhile, we would like to remind you that we will host a webinar today (see this) with former US Attorney Mike Loucks about brand promotion compliance. And now, let the day begin. Have a good one, everyone&amp;#8230;
Forest Labs Responds To FDA For COPD Drug (Pharma Times)
Pfizer Sees A Turnaround For Its Labs (Reuters)
Sanofi May Boost Genzyme Bid As Lab Unit Is Sold (Bloomberg News)
Counterfeit Drug Tally Is Hard To Swallow (Wall Street Journal)
Gilead Quad Pills Supresses HIV At 48 Weeks (Reuters) (Source: Pharmalot)</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3965697</comments>
            <pubDate>Tue, 14 Sep 2010 11:49:31 +0100</pubDate>
            <guid isPermaLink="false">3965697</guid>        </item>
        <item>
            <title>FDA Staffers: Don’t Get Excited About Meta-Analyses</title>
            <link>http://www.medworm.com/index.php?rid=3965702&amp;cid=t_105518_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FxylflFXqUYo%2F</link>
            <description>For the past three years, the reliability of the meta-analysis has been widely debated thanks to such a review that was published in The New England Journal of Medicine about the cardiovascular risks of GlaxoSmithKline&amp;#8217;s Avandia diabetes pill (back story). At issue, of course, is whether a meta-analysis can sufficiently capture the sort of specific information needed to make a solid judgment about risks.
Although such concerns have cropped up concerning other drugs, the FDA has largely avoided taking a position. The other day, however, three FDA staffers - one from the Division of Pulmonary, Allergey and Rheumatology Products in the Office of New Drugs, and two from the Division of Epidemiology in the Office of Surveillance - offered a cautionary word about the utility of the meta-an...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3965702</comments>
            <pubDate>Mon, 13 Sep 2010 12:05:25 +0100</pubDate>
            <guid isPermaLink="false">3965702</guid>        </item>
        <item>
            <title>Coping with c.o.p.d.</title>
            <link>http://www.medworm.com/index.php?rid=3519527&amp;cid=t_105518_111_f&amp;fid=39123&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2Fnursingcomments%2Ftdtc%2F%7E3%2FsfvKxgIImrI%2F</link>
            <description>          Your lungs have 2 main parts: bronchial tubes (also called airways) and alveoli (also called air sacs).  When you breathe, the air moves down your trachea (or wind pipe) through your bronchial tubes and into your alveoli.  From the alveoli, oxygen goes into your blood while carbon dioxide moves out of your blood.  If you have chronic bronchitis, the lining in your bronchial tubes gets red, swollen and full of mucus.  This mucus blocks your tubes, and makes it hard to breathe.  If you have emphysema, your alveoli are irritated.  They get stiff and can&amp;#8217;t hold enough air.  This makes it hard for you to get oxygen into and carbon dioxide out of your blood.  Chronic obstructive pulmonary disease (also called COPD) is a chronic lung disease.  Coping with the dis...</description>
            <author>Nursing Comments</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3519527</comments>
            <pubDate>Thu, 29 Apr 2010 20:16:42 +0100</pubDate>
            <guid isPermaLink="false">3519527</guid>        </item>
        <item>
            <title>FDA Clears Concern over Spiriva Inhaler</title>
            <link>http://www.medworm.com/index.php?rid=3182247&amp;cid=t_105518_111_f&amp;fid=36048&amp;url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FAHeartyLife%2F%7E3%2Ftg0467tgi6A%2F</link>
            <description>Spiriva (tiotropium bromide) is an inhaled medication used to prevent exacerbations (&amp;#8221;attacks&amp;#8221;) caused by COPD, or chronic obstructive pulmonary disease. It&amp;#8217;s taken once per day. There were concerns a while ago about a possible connection between using Spiriva and experiencing a higher risk of stroke and/or heart attacks.
Courtesy of Pfizer Inc.
When this concern was raised, the FDA investigated and has come to the conclusion that this is not an issue with the medication. The FDA came to this conclusion when it and the FDA Pulmonary &amp;#8211; Allergy Drugs Advisory Committee reviewed a 4-year study involving 5,992 patients.
According to the findings,

there was no significant increase in the risk of stroke [0.95 (95% CI 0.70, 1.29)], heart attack [0.73 (95% CI 0.53, 1.00)],...</description>
            <author>A Hearty Life</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3182247</comments>
            <pubDate>Mon, 18 Jan 2010 09:42:20 +0100</pubDate>
            <guid isPermaLink="false">3182247</guid>        </item>
        <item>
            <title>COPD Awareness Month: November</title>
            <link>http://www.medworm.com/index.php?rid=2950801&amp;cid=t_105518_111_f&amp;fid=36048&amp;url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FAHeartyLife%2F%7E3%2FrojYdsqbsFE%2F</link>
            <description>Do you know what COPD stands for? Do you know what it is?
COPD stands for chronic obstructive pulmonary disease. It&amp;#8217;s a respiratory disease that could be virtually eliminated from the world if we would stop smoking altogether. Imagine that. Emphysema and chronic bronchitis fall under the COPD umbrella.
According to the National Heart Lung and Blood Institute,
COPD is now the 4th leading 					cause of death in the United States and also causes long-term disability.
The number of people who have COPD is on the rise — more than 12 million 					are currently diagnosed with it. And it is estimated that another 12 million 					may have COPD but not realize it.
The typical person with COPD is over 45 years old and who either smokes or has smoked. Other people who have it may have a geneti...</description>
            <author>A Hearty Life</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2950801</comments>
            <pubDate>Mon, 02 Nov 2009 07:14:06 +0100</pubDate>
            <guid isPermaLink="false">2950801</guid>        </item>
        <item>
            <title>Upper Body Strength Helps Manage COPD</title>
            <link>http://www.medworm.com/index.php?rid=2744123&amp;cid=t_105518_111_f&amp;fid=36048&amp;url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FAHeartyLife%2F%7E3%2FCGcBbfVRYY4%2F</link>
            <description>People with chronic obstructive pulmonary disease (COPD) may find it difficult to get a lot done on some days. Their difficulty breathing can make moving and getting out a challenge. There&amp;#8217;s not a lot that can be done about this although researchers are looking at ways to improve medications and portable oxygen tanks also make it possible for some people to get out and about.
A new trial has found, though, that simple upper body exercises may be one way of helping people with COPD breathe more easily by strengthening the muscles in the chest.
Twenty-five patients with COPD participated in a trial that either had them doing regular exercise or using dumbbells that helped them strengthen their the pectoralis (the thick muscle, in the upper front of your chest), deltoids (the thick musc...</description>
            <author>A Hearty Life</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2744123</comments>
            <pubDate>Sat, 29 Aug 2009 08:47:23 +0100</pubDate>
            <guid isPermaLink="false">2744123</guid>        </item>
        <item>
            <title>Video Tuesday: COPD</title>
            <link>http://www.medworm.com/index.php?rid=2576665&amp;cid=t_105518_111_f&amp;fid=36048&amp;url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FAHeartyLife%2F%7E3%2FLKsBTQn8it0%2F</link>
            <description>Have you or someone you know been diagnosed with COPD (chronic obstructive pulmonary disease)? Do you understand what COPD is?
Many people only know that COPD has something to do with breathing difficulties, but don&amp;#8217;t really understand what the disease is. This video from National Jewish Health explains to you what COPD is and how it affects your body. Just click on the TV screen below to watch:

~~~~
Image: iStock.com



Share and Enjoy:


	
	
	
	
	
	
	
	
	
	


Post from: Blisstree
Video Tuesday: COPD (Source: A Hearty Life)</description>
            <author>A Hearty Life</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2576665</comments>
            <pubDate>Tue, 07 Jul 2009 08:26:02 +0100</pubDate>
            <guid isPermaLink="false">2576665</guid>        </item>
        <item>
            <title>Video: Understanding COPD - Chronic Obstructive Pulmonary Disease</title>
            <link>http://www.medworm.com/index.php?rid=1975914&amp;cid=t_105518_158_f&amp;fid=36018&amp;url=http%3A%2F%2Fcaregiversbeacon.blogspot.com%2F2008%2F11%2Fvideo-understanding-copd-chronic.html</link>
            <description>(Source: The Caregiver's Beacon - Resources, Links, Ideas, News)</description>
            <author>The Caregiver's Beacon - Resources, Links, Ideas, News</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1975914</comments>
            <pubDate>Fri, 21 Nov 2008 05:56:00 +0100</pubDate>
            <guid isPermaLink="false">1975914</guid>        </item>
        <item>
            <title>Lung Med Linked To Heart Attack And Deaths</title>
            <link>http://www.medworm.com/index.php?rid=1826207&amp;cid=t_105518_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F401313754%2F</link>
            <description>This study is questioning whether this drug is safe for COPD patients. Regulatory reaction is needed to explain this risk.&amp;#8221; 

In a joint statement, Pfizer and Boehringer Ingelheim maintain their analysis of 30 studies involving 19,545 patients found no increased risk of heart attack, stroke or death from any cause among the chronic lung-disease patients taking Spiriva. The results of the study, called Uplift, will be presented on Oct. 5 during the European Respiratory Society 2008 Annual Congress.
&amp;#8220;Once the complete study report for UPLIFT is submitted, the FDA plans to thoroughly review the data to confirm the preliminary findings for UPLIFT and also review all other available information,&amp;#8221; an FDA spokesman tells Bloomberg. 
Meanwhile, a Veterans Affairs study published ...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1826207</comments>
            <pubDate>Wed, 24 Sep 2008 01:22:30 +0100</pubDate>
            <guid isPermaLink="false">1826207</guid>        </item>
        <item>
            <title>National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008</title>
            <link>http://www.medworm.com/index.php?rid=1207230&amp;cid=t_105518_86_f&amp;fid=36669&amp;url=http%3A%2F%2Ffadelibrary.wordpress.com%2F2008%2F02%2F05%2Fnational-knowledge-week-for-chronic-obstructive-pulmonary-disease-2008%2F</link>
            <description>A little late in the week but better late than never is the recording of the fact it&amp;#8217;s the National Knowledge Week for COPD over at the Respiratory Specialist Library from the National Library for Health. Ready information on the following topics is available.


Raising Awareness of Lung Disease
Risk Factors for COPD
Preventing COPD
Access to Stop Smoking Services
Diagnosing COPD
Exercise
Psychological Interventions
Nutrition
Surgical Interventions for COPD
COPD Exacerbations
Evidence Base (Source: Fade Library)</description>
            <author>Fade Library</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1207230</comments>
            <pubDate>Tue, 05 Feb 2008 18:38:40 +0100</pubDate>
            <guid isPermaLink="false">1207230</guid>        </item>
        <item>
            <title>Gain with no pain; just a little strain – physical conditioning for people with cardio-pulmonary impairments.</title>
            <link>http://www.medworm.com/index.php?rid=1186500&amp;cid=t_105518_165_f&amp;fid=36770&amp;url=http%3A%2F%2Fmetaot.com%2Fblogs%2F%255Buser%255D-1</link>
            <description>1. Introduction:
As a basic grade occupational therapist, I frequently encounter people for whom exercise tolerance is the limiting factor of occupational performance. Usually, this is due to physical de-conditioning secondary to inactivity, but occasionally it is due to pathology. This can often be obvious in people with pulmonary or cardiovascular impairments, but less obvious for those with neurological or renal pathology. Reflecting on my undergraduate occupational therapy training, it has not informed me of how best to manage these people as patients. If I knew no better, I might be hesitant to stress people with cardio-pulmonary pathology for fear of straining their already compromised organs. I might just issue loads of equipment and re-organise tasks to reduce occupational stress. ...</description>
            <author>meta-ot blogs</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1186500</comments>
            <pubDate>Sat, 27 Oct 2007 13:38:47 +0100</pubDate>
            <guid isPermaLink="false">1186500</guid>        </item>
        <item>
            <title>Why One COPD Medication Instead of Another?</title>
            <link>http://www.medworm.com/index.php?rid=672213&amp;cid=t_105518_117_f&amp;fid=34444&amp;url=http%3A%2F%2Fblogs.webmd.com%2Fallergies-and-asthma%2F2007%2F06%2Fwhy-one-copd-medication-instead-of.html</link>
            <description>Why Take a Bronchodilator? Bronchodilator inhalers and pills relax the airways, making them wider so that you can breathe more easily. The goal of bronchodilator therapy is to reduce shortness of breath. If you are not short of breath, or if they don't noticeably relieve your shortness of breath, then perhaps you don't need to take a bronchodilator regularly. Discuss this with your doctor.What Side-Effects are Possible from Bronchodilators? Bronchodilator inhalers and pills are stimulants, like the caffeine in coffee and tea. Thus you may experience nervousness (anxiety), shakiness (tremor), a more rapid pulse, insomnia, or stomach upset (nausea). These will only last for the duration of the effect of the bronchodilator (2 to 4 hours for short-acting inhalers, but 12-24 hours for long-acti...</description>
            <author>Allergies and Asthma</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=672213</comments>
            <pubDate>Wed, 13 Jun 2007 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">672213</guid>        </item>
        <item>
            <title>TORCH: Towards a Revolution in COPD Health?  Not really.</title>
            <link>http://www.medworm.com/index.php?rid=488436&amp;cid=t_105518_117_f&amp;fid=34444&amp;url=http%3A%2F%2Fblogs.webmd.com%2Fallergies-and-asthma%2F2007%2F03%2Ftorch-towards-revolution-in-copd-health.html</link>
            <description>Last month, the long-awaited results of the TORCH study of Advair (aka Seretide outside the U.S.)(TM) for patients with moderate to severe COPD were published, but were no doubt disappointing to patients with COPD and investors who own GSK stock. Optimists spun the results as &quot;positive&quot; with a 17% relative reduction in death rates for those taking the combination inhaler for 3 years when compared to those taking the placebo inhaler. However, the absolute difference in deaths during the 3 years from any and all causes was only 2.6% (12.6% vs 15.2%) and this small difference was not statistically significant.An Advair Diskus 500/50mcg (the high dose used by the TORCH study) costs about $270 per month. The drug was associated with a lower hospitalization rate for COPD exacerbations, but 32 pa...</description>
            <author>Allergies and Asthma</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=488436</comments>
            <pubDate>Tue, 20 Mar 2007 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">488436</guid>        </item>
    </channel>
</rss>

